Study of Nivolumab in Patients With Classical Hodgkin’s Lymphoma (Registrational)

Inclusion Criteria:

Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Must have received prior high-dose conditioning chemotherapy followed by autologous stem cell transplant (ASCT) as a part of salvage therapy for cHL (cohort A, B & C - enrollment closed)
Participants may be Brentuximab vedotin- naïve, or may have had prior Brentuximab vedotin treatment (cohort A, B & C - enrollment closed)
Newly diagnosed and previously untreated classical Hodgkin Lymphoma (cohort D)

Exclusion Criteria:

Known central nervous system lymphoma
Participants with nodular lymphocyte-predominant Hodgkin Lymphoma
Prior allogeneic stem cell transplantation (SCT)
Chest radiation ≤ 24 weeks prior to first dose
Carmustine ≥ 600 mg/m² received as part of the pre-transplant conditioning regimen